KORTUC

KORTUC Inc. is a clinical-stage biopharmaceutical company headquartered in Tokyo, Japan. KORTUC's pivotal Phase II study is currently being conducted at The Royal Marsden Hospital and numerous cancer centers across the UK, focusing on locally advanced recurrent breast cancer. The Phase I study was completed in 2019, successfully demonstrating the product's safety and efficacy, with related publications accepted by the Red Journal (ASTRO) in June 2020.